leisure time -WSS

leisure time

author：fashion 2025-09-06 03:57:10 - browse：4

Are biotech’s dog days over? What’s a PIPE? And what can unseat Wegovy?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We dive into the the latest craze in the world of biotech finance, involving hedge funds and some insider information, and explain why not everyone thinks it’s such a good idea. We also discuss a banner month for biotech stocks and the latest twist in obesity research.

For more on what we cover, here’s more on PIPEs; here’s the news from Viking Therapeutics; here’s the latest in MASH; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Wellcome Trust names Røttingen as its new CEO

WSS

Female surgeons have lower rates of long

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Special counsel informs Trump he is target in probe of efforts to overturn 2020 election

Cancer cells are shown to suck energy source from immune cells

How clinical AI models' predictive power can degrade over time

Federal judge rules Oregon’s tough new gun law is constitutional

focus

leisure time

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

What the Wegovy shortage looks like for doctors — and for patients

DIEP, the 'gold standard' of breast reconstruction, is under threat

Better Therapeutics data on benefit with GLP

The high cost of giving birth even with insurance

Humana CEO Bruce Broussard to step down in 2024

Alkermes shareholders re

A fraught question for the kids of Alzheimer’s: Is it coming for us?

BioMarin wins approval for gene therapy to treat hemophilia A

STAT Readout: Today's biotech news includes Sana and Amylyx

leisure time

Nick Jonas talks about managing diabetes along with his career

Europe sees delivery challenges ahead on Alzheimer's therapies

Global childhood vaccinations edge closer to pre

Takeaways from AdvaMed, the largest medical devices conference

Care demand spikes challenge UnitedHealth’s provider arm

How clinical AI models' predictive power can degrade over time

focus

focus

Wikipedia

focus